Insulet Corp
NASDAQ:PODD
Insulet Corp
Operating Income
Insulet Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insulet Corp
NASDAQ:PODD
|
Operating Income
$308.9m
|
CAGR 3-Years
35%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Operating Income
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$2.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
What is Insulet Corp's Operating Income?
Operating Income
308.9m
USD
Based on the financial report for Dec 31, 2024, Insulet Corp's Operating Income amounts to 308.9m USD.
What is Insulet Corp's Operating Income growth rate?
Operating Income CAGR 5Y
44%
Over the last year, the Operating Income growth was 40%. The average annual Operating Income growth rates for Insulet Corp have been 35% over the past three years , 44% over the past five years .
You don't have any saved screeners yet